Schizophrenia and substance use comorbidity: a genome-wide perspective.
Dual diagnosis with substance use disorders (SUDs) consistently contributes to the premature mortality and increased disability observed in schizophrenia. Large genome-wide association studies are providing the information needed to investigate the genetic architecture of psychiatric disorders. Here, we discuss recent genetic investigations of dual diagnosis (i.e., schizophrenia plus a SUD) and how these findings can inform public health messages.
Department of Psychiatry, Yale School of Medicine and VA CT Healthcare Center, West Haven, CT, USA. renato.polimanti@yale.edu.
Renato
R
Polimanti
Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.
Arpana
A
Agrawal
Department of Psychiatry, Yale School of Medicine and VA CT Healthcare Center, West Haven, CT, USA.|Department of Genetics and Department of Neuroscience, Yale School of Medicine, New Haven, CT, USA.
Joel
J
Gelernter
D017831:Diagnosis, Dual (Psychiatry); D055106:Genome-Wide Association Study; D006801:Humans; D012559:Schizophrenia / Q000150:complications / Q000175:diagnosis / Q000209:etiology / Q000235:genetics*; D019966:Substance-Related Disorders / Q000150:complications / Q000175:diagnosis / Q000209:etiology / Q000235:genetics*